THERAPEUTIC VACCINE MULTIPLE SCLEROSIS

DC4U was recently awarded a 2,5 million euro valued Eurostars project for the development a an innovative therapeutic vaccine for Multiple Sclerosis. In this project DC4U and its partners VUmc, piCHEM, University of Bern and MD Biosciences will develop an antigen specific immune therapy based on DC4U’s GlycoDC technology.